- Home
- NBP vs KROS Comparison
NBP vs KROS Comparison
Compare NBP & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NBP | KROS |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | 30 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5M | 206.0M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NBP | KROS |
|---|---|---|
| Price | $1.77 | $10.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $21.86 |
| AVG Volume (30 Days) | ★ 695.4K | 278.7K |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $9.69 |
| 52 Week High | $5.19 | $22.55 |
Technical Indicators
Market Signals| Indicator | NBP | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 40.60 |
| Support Level | $1.67 | $9.74 |
| Resistance Level | $1.95 | $11.55 |
| Average True Range (ATR) | 0.11 | 0.55 |
| MACD | -0.01 | -0.12 |
| Stochastic Oscillator | 17.14 | 11.23 |
Price Performance
Historical ComparisonAbout NBP NovaBridge Biosciences American Depositary Shares
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.